Accordingly, crizotinib, an FDA-approved drug used for the treatment of patients with ALK-positive and ROS1-positive non-small cell lung carcinoma (NSCLC), triggered the nuclear translocation of FOXO3 suggesting an important role of RTKs such as ALK, MET or ROS1 in the regulation of FOXO3. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.